<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35435708</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-6596</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>66</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>Antimicrobial agents and chemotherapy</Title>
          <ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antimicrobial Resistance among Leprosy Patients in Brazil: Real-World Data Based on the National Surveillance Plan.</ArticleTitle>
        <Pagination>
          <StartPage>e0217021</StartPage>
          <MedlinePgn>e0217021</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e02170-21</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/aac.02170-21</ELocationID>
        <Abstract>
          <AbstractText>Brazil ranks second among countries for new cases and first for relapse cases of leprosy worldwide. The Mycobacterium leprae Resistance Surveillance Plan was established. We aimed to present the results of a 2-year follow-up of the National Surveillance Plan in Brazil. A cross-sectional study of leprosy cases was performed to investigate antimicrobial resistance (AMR) in Brazil from October 2018 to September 2020. Molecular screening targeting genes related to dapsone (<i>folP1</i>), rifampin (<i>rpoB</i>), and ofloxacin resistance (<i>gyrA</i>) was performed. During the referral period, 63,520 active leprosy patients were registered in Brazil, and 1,183 fulfilled the inclusion criteria for molecular AMR investigation. In total, only 16 (1.4%) patients had genetic polymorphisms associated with AMR. Of these, 8 (50%) had cases of leprosy relapse, 7 (43.8%) had cases of suspected therapeutic failure with standard treatment, and 1 (6.2%) was a case of new leprosy presentation. M. leprae strains with AMR-associated mutations were found for all three genes screened. Isolates from two patients showed simultaneous resistance to dapsone and rifampin, indicating multidrug resistance (MDR). No significant relationship between clinical variables and the presence of AMR was identified. Our study revealed a low frequency of AMR in Brazil. Isolates were resistant mainly to dapsone, and a very low number of isolates were resistant to rifampin, the main bactericidal agent for leprosy, or presented MDR, reinforcing the importance of the standard World Health Organization multidrug therapy. The greater frequency of AMR among relapsed patients supports the need to constantly monitor this group.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Andrade</LastName>
            <ForeName>Elaine Silva Nascimento</ForeName>
            <Initials>ESN</Initials>
            <Identifier Source="ORCID">0000-0002-8066-8283</Identifier>
            <AffiliationInfo>
              <Affiliation>Coordenação Geral de Doenças em Eliminação - CGDE, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis - DCCI, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Programa de Pós-Graduação em Saúde Coletiva, Faculdade de Medicina, Universidade de Brasília - UnB, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brandão</LastName>
            <ForeName>Jurema Guerrieri</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>Coordenação Geral de Doenças em Eliminação - CGDE, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis - DCCI, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Programa de Pós-Graduação em Ciências Médicas, Faculdade de Medicina, Universidade de Brasília - UnB, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silva</LastName>
            <ForeName>Juliana Souza da</ForeName>
            <Initials>JSD</Initials>
            <AffiliationInfo>
              <Affiliation>Coordenação Geral de Doenças em Eliminação - CGDE, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis - DCCI, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coriolano</LastName>
            <ForeName>Carmelita Ribeiro Filha</ForeName>
            <Initials>CRF</Initials>
            <AffiliationInfo>
              <Affiliation>Coordenação Geral de Doenças em Eliminação - CGDE, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis - DCCI, Secretaria de Vigilância em Saúde, Ministério da Saúde, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rosa</LastName>
            <ForeName>Patricia Sammarco</ForeName>
            <Initials>PS</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Biologia Molecular, Instituto Lauro de Souza Limagrid.419145.c, Bauru, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moraes</LastName>
            <ForeName>Milton Ozório</ForeName>
            <Initials>MO</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório Hanseníase, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferreira</LastName>
            <ForeName>Cynthia de Oliveira</ForeName>
            <Initials>CO</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Biologia Molecular, Fundação Alfredo da Matta, Manaus, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomes</LastName>
            <ForeName>Ciro Martins</ForeName>
            <Initials>CM</Initials>
            <Identifier Source="ORCID">0000-0002-3069-6884</Identifier>
            <AffiliationInfo>
              <Affiliation>Programa de Pós-Graduação em Ciências Médicas, Faculdade de Medicina, Universidade de Brasília - UnB, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Programa de Pós-Graduação em Medicina Tropical, Núcleo de Medicina Tropical, Universidade de Brasília - UnB, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Araújo</LastName>
            <ForeName>Wildo Navegantes de</ForeName>
            <Initials>WN</Initials>
            <AffiliationInfo>
              <Affiliation>Programa de Pós-Graduação em Saúde Coletiva, Faculdade de Medicina, Universidade de Brasília - UnB, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Programa de Pós-Graduação em Medicina Tropical, Núcleo de Medicina Tropical, Universidade de Brasília - UnB, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculdade UnB Ceilândia, Universidade de Brasília - UnB, Brasília, Brazil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto Nacional de Ciência e Tecnologia para Avaliação de Tecnologia em Saúde, Porto Alegre, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
        <NlmUniqueID>0315061</NlmUniqueID>
        <ISSNLinking>0066-4804</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007917">Leprostatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8W5C518302</RegistryNumber>
          <NameOfSubstance UI="D003622">Dapsone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VJT6J7R4TR</RegistryNumber>
          <NameOfSubstance UI="D012293">Rifampin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003622" MajorTopicYN="N">Dapsone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007917" MajorTopicYN="Y">Leprostatic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007918" MajorTopicYN="Y">Leprosy</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009166" MajorTopicYN="N">Mycobacterium leprae</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Brazil</Keyword>
        <Keyword MajorTopicYN="N">DNA</Keyword>
        <Keyword MajorTopicYN="N">M. leprae</Keyword>
        <Keyword MajorTopicYN="N">drug resistance</Keyword>
        <Keyword MajorTopicYN="N">leprosy</Keyword>
        <Keyword MajorTopicYN="N">sequence analysis</Keyword>
        <Keyword MajorTopicYN="N">surveillance</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>12</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35435708</ArticleId>
        <ArticleId IdType="pmc">PMC9112907</ArticleId>
        <ArticleId IdType="doi">10.1128/aac.02170-21</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Han XY, Sizer KC, Velarde-Félix JS, Frias-Castro LO, Vargas-Ocampo F. 2012. The leprosy agents Mycobacterium lepromatosis and Mycobacterium leprae in Mexico. Int J Dermatol
51:952–959. 10.1111/j.1365-4632.2011.05414.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-4632.2011.05414.x</ArticleId>
            <ArticleId IdType="pmc">PMC3397401</ArticleId>
            <ArticleId IdType="pubmed">22788812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization. 2020. Global leprosy (Hansen disease) update, 2019: time to step-up prevention initiatives. Weekly Epidemiological Record
95:417–440. http://www.who.int/wer.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization. 2009. Guidelines for global surveillance of drug resistance in Leprosy. WHO Regional Office for South-East Asia, New Delhi. https://apps.who.int/iris/handle/10665/205158.</Citation>
        </Reference>
        <Reference>
          <Citation>Matsuoka M. 2010. Drug resistance in leprosy. Jpn J Infect Dis
63:1–7. 10.7883/yoken.63.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7883/yoken.63.1</ArticleId>
            <ArticleId IdType="pubmed">20093754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, He J, Liu J, You Y, Yuan L, Wen Y. 2019. Nested PCR and the TaqMan SNP genotyping assay enhanced the sensitivity of drug resistance testing of Mycobacterium leprae using clinical specimens of leprosy patients. PLoS Negl Trop Dis
13:e0007946. 10.1371/journal.pntd.0007946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pntd.0007946</ArticleId>
            <ArticleId IdType="pmc">PMC6934270</ArticleId>
            <ArticleId IdType="pubmed">31881061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chauffour A, Lecorche E, Reibel F, Mougari F, Raskine L, Aubry A, Jarlier V, Cambau E, CNR-MyRMA. 2018. Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015. Clin Microbiol Infect
24:1213.e5–1213.e8. 10.1016/j.cmi.2018.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmi.2018.06.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavania M, Singh I, Turankar R, Ahuja M, Pathak V, Sengupta U, Das L, Kumar A, Darlong J, Nathan R, Maseey A. 2018. Molecular detection of multidrug-resistant Mycobacterium leprae from Indian leprosy patients. J Glob Antimicrob Resist. 12:214–9. 10.1016/j.jgar.2017.10.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jgar.2017.10.010</ArticleId>
            <ArticleId IdType="pubmed">29097343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nery JAC, Sales AM, Hacker MAVB, Moraes MO, Maia RC, Sarno EN, Illarramendi X. 2021. Low rate of relapse after twelve-dose multidrug therapy for hansen’s disease: a 20-year cohort study in a brazilian reference center. PLoS Negl Trop Dis
15:e0009382. 10.1371/journal.pntd.0009382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pntd.0009382</ArticleId>
            <ArticleId IdType="pmc">PMC8118692</ArticleId>
            <ArticleId IdType="pubmed">33939710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Opromolla DVA. 1997. Leprosy therapy. Medicina, Ribeirão Preto
30:345–350. 10.11606/issn.2176-7262.v30i3p345-350. (In Portuguese).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.11606/issn.2176-7262.v30i3p345-350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cambau E, Saunderson P, Matsuoka M, Cole ST, Kai M, Suffys P, Rosa PS, Williams D, Gupta UD, Lavania M, Cardona-Castro N, Miyamoto Y, Hagge D, Srikantam A, Hongseng W, Indropo A, Vissa V, Johnson RC, Cauchoix B, Pannikar VK, Cooreman EAWD, Pemmaraju VRR, Gillini L, WHO surveillance network of antimicrobial resistance in leprosy. 2018. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clin Microbiol Infect
24:1305–1310. 10.1016/j.cmi.2018.02.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmi.2018.02.022</ArticleId>
            <ArticleId IdType="pmc">PMC6286419</ArticleId>
            <ArticleId IdType="pubmed">29496597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>da Silva Rocha A, Cunha M.dG, Diniz LM, Salgado C, Aires MAP, Nery JA, Gallo EN, Miranda A, Magnanini MMF, Matsuoka M, Sarno EN, Suffys PN, de Oliveira MLW. 2012. Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients. J Clin Microbiol
50:1912–1917. 10.1128/JCM.06561-11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.06561-11</ArticleId>
            <ArticleId IdType="pmc">PMC3372169</ArticleId>
            <ArticleId IdType="pubmed">22495562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Contreras Mejía MDC, Porto Dos Santos M, Villarouco da Silva GA, da Motta Passos I, Naveca FG, Souza Cunha M.dG, Moraes MO, de Paula L. 2014. Identification of primary drug resistance to rifampin in mycobacterium leprae strains from leprosy patients in Amazonas State. J Clin Microbiol
52:4359–4360. 10.1128/JCM.01688-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01688-14</ArticleId>
            <ArticleId IdType="pmc">PMC4313315</ArticleId>
            <ArticleId IdType="pubmed">25274993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damasco M, Talhari S, Viana SM, Signorelli M, Saad MH, Andrade LM. 1986. Secondary dapsone-resistant leprosy in Brazil: a preliminary report. Lepr Rev
57:5–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3517536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization. 2016. Global Leprosy Strategy 2016–2020: accelerating towards a leprosy-free world. WHO Regional Office for South-East Asia, New Delhi, India. https://apps.who.int/iris/handle/10665/208824.</Citation>
        </Reference>
        <Reference>
          <Citation>Beltrán-Alzate C, López Díaz F, Romero-Montoya M, Sakamuri R, Li W, Kimura M, Brennan P, Cardona-Castro N. 2016. Leprosy drug resistance surveillance in Colombia: the experience of a sentinel country. PLoS Negl Trop Dis
10:e0005041. 10.1371/journal.pntd.0005041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pntd.0005041</ArticleId>
            <ArticleId IdType="pmc">PMC5051701</ArticleId>
            <ArticleId IdType="pubmed">27706165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh SK, Kumar A, Nath G, Singh TB, Mishra MN. 2018. Resistance to anti leprosy drugs in multi-bacillary leprosy: a cross sectional study from a tertiary care centre in eastern Uttar Pradesh, India. Indian J Dermatol Venereol Leprol
84:275–279. 10.4103/ijdvl.IJDVL_34_16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/ijdvl.IJDVL_34_16</ArticleId>
            <ArticleId IdType="pubmed">29536982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahyuni R, Adriaty D, Iswahyudi I, Rosita C, Agusni I, Izumi S. 2012. Profile of mutation on drug resistance Mycobacterium leprae isolates in Indonesia collected during 2003–2011. Microbiol Indones
6:135–138. 10.5454/mi.6.3.7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5454/mi.6.3.7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalawi I, Tang MM, Osman AS, Ismail M, Bakar RSA, Dony JF, Zainol J, Johar A. 2017. Drug resistance pattern of Mycobacterium leprae from mouse footpad cultivation between 1997 to 2013 in Malaysia. Leprosy Rev
88:463–477. 10.47276/lr.88.4.463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.47276/lr.88.4.463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coulibaly N’Golo D, Roger D, Kakou NG, Solange, Henri K, Christiane AA, Aboubacar S, Philippe BAD, Vagamon B, Mireille D. 2020. Drugs susceptibility testing in leprosy patients from Côte d’Ivoire reveals multidrugs resistance combination cases to dapsone, rifampicin and ofloxacin. Am J Microbiol Res
8:160–163. http://www.sciepub.com/ajmr/abstract/12657.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu D, Zhang Q, Sun Y, Wang C, Zhang Y, Fu X, Chen M, Zhou G, Yu X, Wang J, Liu H, Zhang F. 2015. Drug resistance in Mycobacterium leprae from patients with leprosy in China. Clin Exp Dermatol
40:908–911. 10.1111/ced.12665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ced.12665</ArticleId>
            <ArticleId IdType="pubmed">25991507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosa PS, D’Espindula HRS, Melo ACL, Fontes ANB, Finardi AJ, Belone AFF, Sartori BGC, Pires CAA, Soares CT, Marques FB, Branco FJD, Baptista IMFD, Trino LM, Fachin LRV, Xavier MB, Floriano MC, Ura S, Diório SM, Delanina WFB, Moraes MO, Virmond MCL, Suffys PN, Mira MT. 2020. Emergence and transmission of drug-multidrug-resistant Mycobacterium leprae in a former leprosy colony in the Brazilian Amazon. Clin Infect Dis
70:2054–2061. 10.1093/cid/ciz570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciz570</ArticleId>
            <ArticleId IdType="pmc">PMC7201420</ArticleId>
            <ArticleId IdType="pubmed">31260522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brazil Ministry of Health, Secretary of Health Surveillance. 2020. Technical note no. 8/2020-CGDE/DCCI/SVS/MS: surveillance of antimicrobial resistance in leprosy.
Ministry of Health, Brazil. http://www.aids.gov.br/pt-br/legislacao/nota-tecnica-no-82020-cgdedccisvsms. (In Portuguese).</Citation>
        </Reference>
        <Reference>
          <Citation>Brazil Ministry of Health, Secretary of Health Surveillance. 2016. Guidelines for surveillance, care and elimination of leprosy as a public health problem. Ministry of Health, Brazil. https://www.saude.gov.br/images/pdf/2016/fevereiro/04/diretrizes-eliminacao-hanseniase-367. (In Portuguese).</Citation>
        </Reference>
        <Reference>
          <Citation>Guerrero MI, Colorado CL, Torres JF, León CI. 2013. Is drug-resistant Mycobacterium leprae a real cause for concern? First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment. biomedica
34:137–147. 10.7705/biomedica.v34i0.1686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7705/biomedica.v34i0.1686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chokkakula S, Chen Z, Wang L, Jiang H, Chen Y, Shi Y, Zhang W, Gao W, Yang J, Li J, Li X, Shui T, He J, Shen L, Liu J, Wang D, Wang H, Chen H, Kuang Y, Li B, Chen Z, Wu A, Yu M, Yan L, Suryadevara NC, Vissa V, Liu W, Wang H. 2019. Molecular surveillance of antimicrobial resistance and transmission pattern of Mycobacterium leprae in Chinese leprosy patients. Emerg Microbes Infect
8:1479–1489. 10.1080/22221751.2019.1677177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/22221751.2019.1677177</ArticleId>
            <ArticleId IdType="pmc">PMC6818117</ArticleId>
            <ArticleId IdType="pubmed">31621517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahajan NP, Lavania M, Singh I, Nashi S, Preethish-Kumar V, Vengalil S, Polavarapu K, Pradeep-Chandra-Reddy C, Keerthipriya M, Mahadevan A, Yasha TC, Nandeesh BN, Gnanakumar K, Parry GJ, Sengupta U, Nalini A. 2020. Evidence for Mycobacterium leprae drug resistance in a large cohort of leprous neuropathy patients from India. Am J Trop Med
102:547–552. 10.4269/ajtmh.19-0390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4269/ajtmh.19-0390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avanzi C, Maia RC, Benjak A, Nery JA, Sales AM, Miranda A, Duppre NC, Nogueira Brum Fontes A, Pereira da Silva T, Olmo Pinheiro R, Neves-Manta F, Moreira SJM, Busso P, Sarno EN, Suffys PN, Cole ST, Moraes MO. 2020. Emergence of Mycobacterium leprae rifampin resistance evaluated by whole-genome sequencing after 48 years of irregular treatment. Antimicrob Agents Chemother
64. 10.1128/AAC.00330-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00330-20</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrade ESN, Brandão JG, da Silva JS, Kurizky PS, Rosa PS, de Araújo WN, Gomes CM. 2021. A systematic review and meta-analysis of studies on the diagnostic accuracy and screening of tests to detect antimicrobial resistance in leprosy. Diagn Microbiol Infect Dis
100:115325. 10.1016/j.diagmicrobio.2021.115325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diagmicrobio.2021.115325</ArticleId>
            <ArticleId IdType="pubmed">33556650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brazil Ministry of Health, Secretary of Health Surveillance. 2018. Technical note no. 31 CGHDE/CGLAB/DEVIT/SVS/MS: implementation of the protocol for the investigation of drug resistance in leprosy and establishment of the sample shipment flow.
Ministry of Health, Brazil.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization. 2017. A guide for surveillance of antimicrobial resistance in leprosy. World Health Organization, Regional Office for South-East Asia, New Delhi, India. https://apps.who.int/iris/rest/bitstreams/1137285/retrieve.</Citation>
        </Reference>
        <Reference>
          <Citation>Sekar B, Arunagiri K, Kumar BN, Narayanan S, Menaka K, Oommen PK. 2011. Detection of mutations in folP1, rpoB and gyrA genes of M. leprae by PCR- direct sequencing - a rapid tool for screening drug resistance in leprosy. Lepr Rev
82:36–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21644470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar S, Stecher G, Tamura K. 2016. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol
33:1870–1874. 10.1093/molbev/msw054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/molbev/msw054</ArticleId>
            <ArticleId IdType="pmc">PMC8210823</ArticleId>
            <ArticleId IdType="pubmed">27004904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization. 2017. Global leprosy strategy 2016–2020. Accelerating towards a leprosy-free world. Monitoring and Evaluation Guide. WHO Regional Office for South-East Asia, New Delhi, India. https://apps.who.int/iris/handle/10665/254907.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
